PEGylated Mutated Clostridium botulinum Toxin
AssigneeMERZ PHARMA GmbH & CO. KGaA
InventorsJürgen FREVERT, Volker Specht
Life of this patent
Estimating the term…
Loading patent…
AssigneeMERZ PHARMA GmbH & CO. KGaA
InventorsJürgen FREVERT, Volker Specht
Estimating the term…
The invention relates to a modified botulinum toxin comprising a natural heavy chain and a modified light chain, characterized in that the modification of the light chain resides in that it comprises (i) an extension of the chain on its N-terminus which has the structure —(C)n-(tag)m-(X)l— in the direction from the N- to the C-terminal end, wherein C represents a cysteine residue, tag represents any tag and X represents the residue of any naturally occurring amino acid, n represents an integer from 1 to 50, m represents 0 or 1, and l represents 0 or an integer from 1 to 50, and in that (ii) at least one of the cysteine residues in the extension of the chain is coupled to at least one chain of PEG.
1-22. (canceled)
A pharmaceutical composition comprising a modified botulinum toxin, the modified botulinum toxin comprising a natural heavy chain and a modified light chain, wherein the light chain comprises at least one and at most 20 amino acid residues occurring naturally at its N-terminus being mutated to a cysteine residue, and at least one chain of PEG coupled to at least one cysteine residue in said 20 amino acid residues at said N-terminus.
A method of treating dystonia or for removing facial wrinkles, the method comprising treatment of a subject with a modified botulinum toxin, the modified botulinum toxin comprising a natural heavy chain and a modified light chain, characterized in that the modification of the light chain (i) comprises an extension of the chain on its N-terminus which has the structure —(C)n-(tag)m-(X)l— in the direction from the N- to the C-terminal end, wherein:
Dependencies are inferred from the claim text.